-
04:01:57 AM

MRTX Stock News

01/19/23 5:00 PM
Nasdaq : MRTX
clinical trial
Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133
Mirati Therapeutics, Inc., announced today the U.S. Food and Drug Administration has cleared the Investigational New Drug application of MRTX1133, a potential first-in-class oral KRAS G12D selective inhibitor for clinical evaluation. This particular mutation has been difficult to target, and we are confident in our novel oral formulation strategy, which...
RHEA-AI
neutral
12/21/22 5:00 PM
Nasdaq : MRTX
clinical trial
Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for adagrasib (KRAZATI TM) in combination with cetuximab in patients with KRAS G12C -mutated advanced colorectal cancer (CRC) whose cancer has progressed following prior treatment with chemotherapy and an
RHEA-AI
positive
12/13/22 5:00 AM
NYSE, Nasdaq : QGEN, MRTX
fda approval
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
QIAGEN has announced the U.S. Food and Drug Administration approval of its therascreen ® KRAS RGQ PCR kit as a companion diagnostic test to Mirati Therapeutic’ s drug KRAZATI ® for non-small cell lung cancer. QIAGEN and Mirati Therapeutics, Inc., a targeted oncology company, announced their cooperation in May 2021.
RHEA-AI
very positive
12/12/22 6:42 PM
Nasdaq : MRTX
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI ™ ( adagrasib), a targeted treatment option for adult patients with KRAS
RHEA-AI
very positive
12/05/22 6:05 PM
Nasdaq : MRTX
Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRAS G12C mutation Findings will be presented on December 7 at the 2022 ESMO Immuno-Oncology Annual Congress, as an
RHEA-AI
neutral